{"id":6974,"date":"2021-03-18T15:28:06","date_gmt":"2021-03-18T22:28:06","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6974"},"modified":"2021-03-19T15:29:02","modified_gmt":"2021-03-19T22:29:02","slug":"mavrilimumab-in-patients-with-severe-covid-19-pneumonia-and-systemic-hyperinflammation-mash-covid-an-investigator-initiated-multicentre-double-blind-randomised-placebo-controlled-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/18\/mavrilimumab-in-patients-with-severe-covid-19-pneumonia-and-systemic-hyperinflammation-mash-covid-an-investigator-initiated-multicentre-double-blind-randomised-placebo-controlled-trial\/","title":{"rendered":"Mavrilimumab in Patients with Severe COVID-19 Pneumonia and Systemic Hyperinflammation (MASH-COVID): An Investigator Initiated, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The monoclonal antibody treatment mavrilimumab did not significantly lower the proportion of patients with severe COVID-19 who were alive and off oxygen therapy at day 14 compared to placebo (52% vs 47%, OR = 1.48, 95% CI: 0.43-5.16) in a multicenter, double-blind placebo-controlled randomized trial (n=40). Patients were included in the study if they were hospitalized, had COVID-19 pneumonia, low blood oxygen levels, and a C-reactive protein concentration &gt;5 mg\/dL. Patients who were mechanically ventilated were excluded.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Cremer et al.\u00a0(Mar 18, 2021). Mavrilimumab in Patients with Severe COVID-19 Pneumonia and Systemic Hyperinflammation (MASH-COVID): An Investigator Initiated, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet Rheumatology. <\/span><\/i><a href=\"https:\/\/www.thelancet.com\/journals\/lanrhe\/article\/PIIS2665-9913(21)00070-9\/fulltext\"><span style=\"font-weight: 400\">https:\/\/www.thelancet.com\/journals\/lanrhe\/article\/PIIS2665-9913(21)00070-9\/fulltext<\/span><\/a><span style=\"font-weight: 400\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The monoclonal antibody treatment mavrilimumab did not significantly lower the proportion of patients with severe COVID-19 who were alive and off oxygen therapy at day 14 compared to placebo (52% vs 47%, OR = 1.48, 95% CI: 0.43-5.16) in a multicenter, double-blind placebo-controlled randomized trial (n=40). Patients were included in the study if they were&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/18\/mavrilimumab-in-patients-with-severe-covid-19-pneumonia-and-systemic-hyperinflammation-mash-covid-an-investigator-initiated-multicentre-double-blind-randomised-placebo-controlled-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-6974","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6974"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6974\/revisions"}],"predecessor-version":[{"id":6975,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6974\/revisions\/6975"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6974"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}